ArticleAlimentary pharmacology & therapeutics2013
Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases.Advances in therapy · 2015Pooled it
- Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2026Article
- An education-based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study).United European gastroenterology journal · 2023Article
- What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials.Patient preference and adherence · 2023Article
- Beliefs About Medicines and Adherence to Treatment in Turkish Patients with Inflammatory Bowel Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Self-Reported Medication Adherence Among Patients with Ulcerative Colitis in Japan and the United Kingdom: A Secondary Analysis for Cross-Cultural Comparison.Patient preference and adherence · 2022Article
- Article
- Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.Intestinal research · 2020Review
- Content and Usability Evaluation of Medication Adherence Mobile Applications for Use in Pediatrics.Journal of pediatric psychology · 2019Article
- Medication adherence in inflammatory bowel disease.Intestinal research · 2017Review
- Adherence in ulcerative colitis: an overview.Patient preference and adherence · 2017Review
- What strategies do ulcerative colitis patients employ to facilitate adherence?Patient preference and adherence · 2017Article
- Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools.JMIR mHealth and uHealth · 2016Article
- Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Current approaches to the management of new-onset ulcerative colitis.Clinical and experimental gastroenterology · 2014Review
- Maintaining persistence and adherence with subcutaneous growth-hormone therapy in children: comparing jet-delivery and needle-based devices.Patient preference and adherence · 2014Article
- Real-World Adherence and Relapse Risk in Mesalamine Treatment for Ulcerative Colitis: Insights from a Large Japanese Medical Claims Database.Inflammatory intestinal diseasesArticle
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMaintenance therapy with 5-aminosalicylic acid (5-ASA) is a key strategy for preventing relapse in many patients with inflammatory bowel disease (IBD). Factors which disrupt 5-ASA delivery, such as non-adherence and 5-ASA switches, may destabilise symptom control.
aimTo investigate the impact of non-adherence and medication switches on stable symptom control in UK patients with IBD.
methodsA retrospective cohort study was conducted using a UK dispensing database. Adherence was analysed in randomised matched samples for each of the six leading oral mesalazine formulations, measured by medication possession ratio (MPR); MPR ≥80% was classified as adherent. Relationships among adherence, switch and relapse were analysed over 18 months in patients receiving continuous mesalazine therapy throughout a 6-month baseline period (primary subgroup analysis). Relapses of active ulcerative colitis were identified using a doubling of MPR as a proxy.
resultsOnly 39% of patients in the matched samples (n = 1200) were classed as adherent. No significant differences in adherence were observed among mesalazine formulations. In the primary subgroup analysis (n = 568), non-adherent patients had a significantly greater risk of relapse than adherent patients (RR = 1.44, 95% CI = 1.08-1.94; P = 0.014). Among adherent patients (n = 276), those who switched had a 3.5-fold greater risk of relapse than those who did not switch (95% CI = 1.16-10.62; P = 0.008).
conclusionsBoth non-adherence and mesalazine switches in adherent patients were associated with significant increases in the risk of relapse, suggesting that disruption of mesalazine maintenance therapy may destabilise symptom control. These findings provide evidence to advocate caution when considering mesalazine switches for stable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.